Galunisertib
- Generic Name
- Galunisertib
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19N5O
- CAS Number
- 700874-72-2
- Unique Ingredient Identifier
- 3OKH1W5LZE
- Background
Galunisertib has been used in trials studying the basic science and treatment of Glioma, Neoplasms, Solid Tumor, GLIOBLASTOMA, and Prostate Cancer, among others.
Pipeline Advances in Head and Neck Cancer Treatment: Over 100 Drugs in Development for 2025
• DelveInsight's latest report reveals a robust pipeline with over 80 companies developing 100+ drug candidates for head and neck cancer, highlighting significant research momentum in this therapeutic area.
• Key late-stage candidates include Debiopharm/Merck's xevinapant, GlaxoSmithKline's dostarlimab, and QBiotics' tigilanol tiglate, each employing novel mechanisms to potentially improve outcomes for patients with limited treatment options.
• Multiple clinical trials are underway testing innovative approaches including IAP inhibitors, immune checkpoint blockers, and oncolytic therapies, with several Phase III studies expected to deliver results that could reshape treatment paradigms.
Combination Immunotherapies Show Promise in Pancreatic Cancer Treatment
• Combining anti-PD-(L)1 antibodies with hyaluronidase enhances tumor growth inhibition by remodeling the stroma and improving drug delivery in pancreatic cancer models.
• Blocking IL-6 in combination with anti-PD-L1 antibodies inhibits tumor volume and increases survival in preclinical pancreatic cancer models, warranting clinical verification.
• Combining CD40 agonists with PD-L1 blockade improves overall survival and promotes anti-tumor immunity in orthotopic pancreatic cancer mouse models.
• Inhibiting the CXCL12/CXCR4 pathway alongside anti-PD-(L)1 therapy modulates immunosuppression and demonstrates synergistic effects in treating pancreatic cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath